I agree with AML, but everyone should determine their own success.
i believe that from preclinical and historical data, bisantrene is better than doxorubicin. it becomes trial design, how difficult it will be to recruit for the trial and whether there will be statistical difference. my opinion is proving it will be the tricky part. But if we can show it as better statistically, I believe we can get oncologist on board much faster than other trial designs. It's why I like this clinical pathway, despite the difficulty that I see
Ann: Race Strategic Update March 2021, page-384
-
- There are more pages in this discussion • 136 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.53 |
Change
-0.060(3.79%) |
Mkt cap ! $259.9M | |||
| Open | High | Low | Value | Volume |
| $1.54 | $1.56 | $1.53 | $130.2K | 84.73K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4993 | $1.53 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.58 | 10451 | 1 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |